Vical (VICL) Reports Publication of Two Articles About Vaxfectin
More News related to VICL
- Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
- Vical Added to NASDAQ Biotechnology Index
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
- Vical (VICL) Misses Q3 EPS by 1c; Revenues Above Consensus
More News related to Corporate News
- Sprint Nextel (S) Completes Tender Offer for iPCS, Inc. (IPCS)
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Vical Incorporated (NASDAQ: VICL) announced today the publication of two articles regarding the company's Vaxfectin adjuvant in a special issue of Vaccine. One article highlighted preclinical data showing Vaxfectin's improvement of performance with Sanofi-Pasteur Fluzone seasonal influenza vaccine; the other analyzed how Vaxfectin works.
Vical authors Hartikka et al. demonstrated in mice that commercially acquired Sanofi-Pasteur Fluzone seasonal influenza vaccine formulated with the company's patented Vaxfectin adjuvant produced up to 200-fold higher antibody responses and at least a 10-fold dose-sparing effect compared with unformulated vaccine. Vaxfectin-formulated vaccine also produced a more balanced T-helper cell immune response than unformulated vaccine, suggesting the ability to enhance vaccine effectiveness. In addition, a low ratio of Vaxfectin to vaccine was found to favor T-cell immune responses, while a higher ratio of Vaxfectin to vaccine was found to favor antibody immune responses. The authors concluded that increased T-cell or antibody responses may be preferentially induced by changing the Vaxfectin(R) to vaccine ratio.
Vical authors Shlapobersky et al. explored the mechanism of action of Vaxfectin when used in combination with a protein-based seasonal influenza vaccine. They determined that the ratio of Vaxfectin to protein changes the particle size of the vaccine, which in turn modulates the profile of immune response. The profile was determined both locally at the site of injection and systemically in serum by analyzing a panel of biomarkers by gene expression profiling. The authors concluded that some of these biomarkers may be useful in tailoring the ratio of Vaxfectin to vaccine to produce the optimal balance between T-cell and antibody responses for specific applications.
Related Categories
Corporate NewsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
